SYNCOM FORMULATIONS (INDIA)
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.53 | 0.27 | 0.21 | 0.23 | 0.13 |
| CEPS(Rs) | 0.58 | 0.32 | 0.26 | 0.28 | 0.17 |
| DPS(Rs) | - | - | 0.03 | - | 0.02 |
| Book NAV/Share(Rs) | 3.64 | 3.07 | 2.72 | 2.52 | 1.50 |
| Tax Rate(%) | 24.54 | 25.44 | 24.47 | 24.39 | 33.65 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.64 | 11.26 | 8.87 | 9.12 | 8.96 |
| EBIT Margin(%) | 14.27 | 14.59 | 13.37 | 12.79 | 8.77 |
| Pre Tax Margin(%) | 14.09 | 12.89 | 11.85 | 11.92 | 8.59 |
| PAT Margin (%) | 10.63 | 9.61 | 8.95 | 9.01 | 5.70 |
| Cash Profit Margin (%) | 11.75 | 11.40 | 10.97 | 10.81 | 7.39 |
| Performance Ratios | |||||
| ROA(%) | 12.02 | 6.45 | 5.85 | 8.04 | 5.78 |
| ROE(%) | 15.69 | 9.30 | 8.48 | 11.83 | 9.32 |
| ROCE(%) | 18.77 | 10.98 | 9.68 | 13.72 | 13.28 |
| Asset Turnover(x) | 1.13 | 0.67 | 0.65 | 0.89 | 1.01 |
| Sales/Fixed Asset(x) | 3.31 | 2.22 | 2.21 | 2.28 | 2.12 |
| Working Capital/Sales(x) | 2.21 | 1.57 | 3.27 | 3.57 | 6.67 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.30 | 0.45 | 0.45 | 0.44 | 0.47 |
| Receivable days | 82.75 | 123.89 | 116.42 | 94.33 | 90.83 |
| Inventory Days | 24.49 | 29.30 | 33.13 | 24.52 | 25.15 |
| Payable days | 45.68 | 69.17 | 62.08 | 79.52 | 140.62 |
| Valuation Parameters | |||||
| PER(x) | 31.28 | 41.52 | 27.63 | 46.32 | 14.60 |
| PCE(x) | 28.31 | 34.99 | 22.54 | 38.62 | 11.26 |
| Price/Book(x) | 4.52 | 3.65 | 2.17 | 4.22 | 1.31 |
| Yield(%) | - | - | 0.51 | - | 1.02 |
| EV/Net Sales(x) | 3.33 | 4.01 | 2.81 | 4.43 | 0.86 |
| EV/Core EBITDA(x) | 21.66 | 24.45 | 18.24 | 30.42 | 8.26 |
| EV/EBIT(x) | 23.35 | 27.47 | 20.99 | 34.66 | 9.85 |
| EV/CE(x) | 4.47 | 2.93 | 1.85 | 3.16 | 1.23 |
| M Cap / Sales | 3.33 | 3.99 | 2.47 | 4.17 | 0.83 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 76.55 | 17.45 | 2.09 | 18.85 | 0.50 |
| Core EBITDA Growth(%) | 65.76 | 25.14 | 7.72 | 65.57 | 0.03 |
| EBIT Growth(%) | 72.74 | 28.20 | 6.66 | 73.35 | -0.16 |
| PAT Growth(%) | 95.28 | 26.13 | 1.42 | 87.87 | 1.72 |
| EPS Growth(%) | 95.28 | 26.14 | -6.96 | 70.10 | 1.66 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 0.25 | 0.32 | 0.27 | 0.11 |
| Current Ratio(x) | 4.41 | 2.55 | 1.61 | 1.79 | 1.47 |
| Quick Ratio(x) | 3.74 | 2.35 | 1.42 | 1.54 | 1.30 |
| Interest Cover(x) | 76.75 | 8.59 | 8.81 | 14.58 | 48.48 |
| Total Debt/Mcap(x) | - | 0.07 | 0.15 | 0.06 | 0.08 |
Compare Financial Ratios of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,561.3 Cr | -0.9% | -2.1% | -15.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹404,804.0 Cr | -0.2% | 3.6% | -7.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,764.0 Cr | -2.4% | 9.1% | 13.4% | Stock Analytics | |
| CIPLA | ₹126,807.0 Cr | -5.7% | 4% | 6.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,099.0 Cr | -0.3% | 1.3% | 8.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,707.0 Cr | 0.1% | 1.2% | -2.8% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -0.9% |
-2.1% |
-15.1% |
| SENSEX | 0.3% |
3.6% |
5.5% |
You may also like the below Video Courses
